Have you been diagnosed with pleural fluid, and have been referred for a pleural fluid drainage? If so, you may be able to participate in a research registry to help us learn more about lung cancer.

The purpose of this study is to understand how monitoring symptoms at home after lung cancer diagnosis could impact quality of care and the likelihood of returning to the hospital. This study will also help us understand whether symptom monitoring in patients with advanced lung cancer is helpful for patients and the clinical teams who care for them.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you been diagnosed with HER-2 positive breast cancer and have already received treatment with chemotherapy followed by surgery? Was your breast cancer still present at time of surgery and removed? If so you may be eligible for a trial to see if a combination of T-DM1 with tucatinib is better than receiving T-DM1 alone at preventing your cancer from returning.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

Have you ever been diagnosed with HER2 positive metastatic breast cancer and had disease progression after receiving at least one type of therapy? If so you may be eligible for a clinical trial that tests niraparib in combination with trastuzumab.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

Have you been diagnosed with locally advanced or metastatic hepatocellular carcinoma? If so, you may be a good fit to help us learn if adding tiragolumab to standard therapy could help you and others with your condition

In this study, we want to learn if a combination of two drugs (fianlimab and cemiplimab) is an effective treatment compared to a drug called pembrolizumab for people who have had melanoma removal surgery but are still at high risk for recurrence of the disease.

This is a Phase 1b/2, multicenter, open-label, basket study evaluating ACR-368, an adenosine triphosphate-competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2, as monotherapy and in combination with ultralow-dose gemcitabine (ULDG), in the treatment of subjects with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma (hereafter referred to as ovarian, endometrial, and urothelial, respectively).